{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:29:23Z","timestamp":1789612163247,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP17im0210606"],"award-info":[{"award-number":["JP17im0210606"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP20im0210111"],"award-info":[{"award-number":["JP20im0210111"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The University of Osaka"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gastric Cancer"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The tyrosine kinase inhibitor (TKI) imatinib targets KIT and PDGFRA, offering significant therapeutic benefits in advanced gastrointestinal stromal tumors (GISTs). However, the high rate of recurrence following treatment discontinuation suggests that drug-tolerant persister cells (DTPs) may contribute to therapy resistance. Elucidating the mechanisms underlying DTP survival is critical for the development of curative strategies. This study aimed to investigate the role of yes-associated protein (YAP) in DTP survival and to evaluate the efficacy of combining imatinib with YAP inhibitors as a potential therapeutic approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Imatinib-sensitive GIST cell lines were treated with imatinib to generate DTPs. YAP activity was assessed via western blotting, fluorescence immunostaining, and nuclear-cytoplasmic fractionation. Proliferation and apoptosis assays were conducted to evaluate sensitivity to YAP inhibitors, such as verteporfin. Xenograft mouse models were used to assess the efficacy of combination therapy with imatinib and verteporfin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>DTPs exhibited increased nuclear localization and activity of YAP, which was reversible upon imatinib withdrawal. YAP inhibitors reduced nuclear YAP levels and showed greater efficacy in DTPs than in parental cells. Combination therapy with imatinib and verteporfin significantly suppressed DTP proliferation and induced apoptosis in vitro. In xenograft models, the combination therapy delayed tumor regrowth after treatment cessation compared to imatinib monotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>YAP activity was elevated in GIST DTPs, and YAP inhibitors effectively suppressed this activity. The combination of imatinib and YAP inhibitors enhanced tumor growth suppression. These findings underscore the pivotal role of YAP in DTP survival and demonstrate the therapeutic potential of combining imatinib with YAP inhibitors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10120-025-01657-z","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T18:12:24Z","timestamp":1757355144000},"page":"1101-1113","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Targeting yes-associated protein to overcome imatinib resistance in gastrointestinal stromal tumor drug-tolerant persister cells"],"prefix":"10.1007","volume":"28","author":[{"given":"Takashi","family":"Yokouchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2397-1478","authenticated-orcid":false,"given":"Tsuyoshi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshirou","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukinori","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyoshi","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuro","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaomi","family":"Hagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Momose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Makino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiko","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Serada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiichi","family":"Hirota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyokazu","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuji","family":"Naka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Doki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,8]]},"reference":[{"key":"1657_CR1","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1053\/j.semdp.2006.09.001","volume":"23","author":"M Miettinen","year":"2006","unstructured":"Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006;23:70\u201383.","journal-title":"Semin Diagn Pathol"},{"key":"1657_CR2","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1056\/NEJMoa020461","volume":"347","author":"GD Demetri","year":"2002","unstructured":"Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472\u201380.","journal-title":"N Engl J Med"},{"key":"1657_CR3","volume":"2014","author":"N Iqbal","year":"2014","unstructured":"Iqbal N. Imatinib: a breakthrough of targeted therapy in cancer. Chemother Res Pract. 2014;2014:357027.","journal-title":"Chemother Res Pract"},{"key":"1657_CR4","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s11523-023-00960-y","volume":"18","author":"M Mohammadi","year":"2023","unstructured":"Mohammadi M, IJzerman NS, Hollander DD, Bleckman RF, Oosten AW, Desar IME, et al. Improved efficacy of first-line imatinib in advanced gastrointestinal stromal tumors (GIST): the Dutch GIST registry data. Target Oncol. 2023;18:415\u201323.","journal-title":"Target Oncol"},{"key":"1657_CR5","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1093\/annonc\/mds587","volume":"24","author":"A Patrikidou","year":"2013","unstructured":"Patrikidou A, Chabaud S, Ray-Coquard I, Bui BN, Adenis A, Rios M, et al. Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French sarcoma group randomised, phase III trial. Ann Oncol. 2013;24:1087\u201393.","journal-title":"Ann Oncol"},{"key":"1657_CR6","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S1470-2045(24)00318-8","volume":"25","author":"JY Blay","year":"2024","unstructured":"Blay JY, Devin Q, Duffaud F, Toulmonde M, Firmin N, Collard O, et al. Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2024;25:1163\u201375.","journal-title":"Lancet Oncol"},{"key":"1657_CR7","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1038\/s41416-021-01566-9","volume":"125","author":"T Ishida","year":"2021","unstructured":"Ishida T, Takahashi T, Kurokawa Y, Nishida T, Hirota S, Serada S, et al. Targeted therapy for drug-tolerant persister cells after imatinib treatment for gastrointestinal stromal tumours. Br J Cancer. 2021;125:1511\u201322.","journal-title":"Br J Cancer"},{"key":"1657_CR8","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","volume":"141","author":"SV Sharma","year":"2010","unstructured":"Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell. 2010;141:69\u201380.","journal-title":"Cell"},{"key":"1657_CR9","doi-asserted-by":"publisher","first-page":"10690","DOI":"10.1038\/ncomms10690","volume":"7","author":"M Ramirez","year":"2016","unstructured":"Ramirez M, Rajaram S, Steininger RJ, Osipchuk D, Roth MA, Morinishi LS, et al. Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells. Nat Commun. 2016;7:10690.","journal-title":"Nat Commun"},{"key":"1657_CR10","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/s41586-021-03796-6","volume":"596","author":"Y Oren","year":"2021","unstructured":"Oren Y, Tsabar M, Cuoco MS, Amir-Zilberstein L, Cabanos HF, H\u00fctter JC, et al. Cycling cancer persister cells arise from lineages with distinct programs. Nature. 2021;596:576\u201382.","journal-title":"Nature"},{"key":"1657_CR11","first-page":"2737","volume":"133","author":"T Takahashi","year":"2013","unstructured":"Takahashi T, Serada S, Ako M, Fujimoto M, Miyazaki Y, Nakatsuka R, et al. New findings of kinase switching in gastrointestinal stromal tumor under imatinib using phosphoproteomic analysis. Int J Cancer. 2013;133:2737\u201343.","journal-title":"Int J Cancer"},{"key":"1657_CR12","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1152\/physrev.00005.2014","volume":"94","author":"S Piccolo","year":"2014","unstructured":"Piccolo S, Dupont S, Cordenonsi M. The biology of YAP\/TAZ: hippo signaling and beyond. Physiol Rev. 2014;94:1287\u2013312.","journal-title":"Physiol Rev"},{"key":"1657_CR13","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1038\/s41556-018-0142-z","volume":"20","author":"A Totaro","year":"2018","unstructured":"Totaro A, Panciera T, Piccolo S. YAP\/TAZ upstream signals and downstream responses. Nat Cell Biol. 2018;20:888\u201399.","journal-title":"Nat Cell Biol"},{"key":"1657_CR14","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ccell.2019.12.006","volume":"37","author":"KJ Kurppa","year":"2020","unstructured":"Kurppa KJ, Liu Y, To C, Zhang T, Fan M, Vajdi A, et al. Treatment-induced tumor dormancy through YAP-mediated transcriptional reprogramming of the apoptotic pathway. Cancer Cell. 2020;37:104-22.e12.","journal-title":"Cancer Cell"},{"key":"1657_CR15","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1038\/s41467-024-47423-0","volume":"15","author":"F Haderk","year":"2024","unstructured":"Haderk F, Chou YT, Cech L, Fern\u00e1ndez-M\u00e9ndez C, Yu J, Olivas V, et al. Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer. Nat Commun. 2024;15:3741.","journal-title":"Nat Commun"},{"key":"1657_CR16","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s00535-024-02180-1","volume":"60","author":"X Wu","year":"2025","unstructured":"Wu X, Yamashita K, Matsumoto C, Zhang W, Ding M, Harada K, et al. YAP acts as an independent prognostic marker and regulates growth and metastasis of gastrointestinal stromal tumors via FBXW7-YAP pathway. J Gastroenterol. 2025;60:275\u201384.","journal-title":"J Gastroenterol"},{"key":"1657_CR17","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/s41416-019-0688-y","volume":"122","author":"Y Saito","year":"2020","unstructured":"Saito Y, Takahashi T, Obata Y, Nishida T, Ohkubo S, Nakagawa F, et al. TAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-na\u00efve and imatinib-resistant gastrointestinal stromal tumours. Br J Cancer. 2020;122:658\u201367.","journal-title":"Br J Cancer"},{"key":"1657_CR18","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.celrep.2015.09.014","volume":"13","author":"W Wang","year":"2015","unstructured":"Wang W, Li N, Li X, Tran MK, Han X, Chen J. Tankyrase inhibitors target YAP by stabilizing Angiomotin family proteins. Cell Rep. 2015;13:524\u201332.","journal-title":"Cell Rep"},{"key":"1657_CR19","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1002\/ijc.30666","volume":"140","author":"T Sugase","year":"2017","unstructured":"Sugase T, Takahashi T, Serada S, Nakatsuka R, Fujimoto M, Ohkawara T, et al. Suppressor of cytokine signaling-1 gene therapy induces potent antitumor effect in patient-derived esophageal squamous cell carcinoma xenograft mice. Int J Cancer. 2017;140:2608\u201321.","journal-title":"Int J Cancer"},{"key":"1657_CR20","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.ccell.2018.01.005","volume":"33","author":"LMN Wu","year":"2018","unstructured":"Wu LMN, Deng Y, Wang J, Zhao C, Rao R, Xu L, et al. Programming of Schwann cells by Lats1\/2-TAZ\/YAP signaling drives malignant peripheral nerve sheath tumorigenesis. Cancer Cell. 2018;33:292\u2013308.","journal-title":"Cancer Cell"},{"key":"1657_CR21","doi-asserted-by":"publisher","first-page":"6975","DOI":"10.1158\/0008-5472.CAN-17-1525","volume":"77","author":"T Sugase","year":"2017","unstructured":"Sugase T, Takahashi T, Serada S, Fujimoto M, Hiramatsu K, Ohkawara T, et al. SOCS1 gene therapy improves radiosensitivity and enhances irradiation-induced DNA damage in esophageal squamous cell carcinoma. Cancer Res. 2017;77:6975\u201386.","journal-title":"Cancer Res"},{"key":"1657_CR22","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1002\/gcc.22438","volume":"56","author":"T Takahashi","year":"2017","unstructured":"Takahashi T, Elzawahry A, Mimaki S, Furukawa E, Nakatsuka R, Nakamura H, et al. Genomic and transcriptomic analysis of imatinib resistance in gastrointestinal stromal tumors. Genes Chromosomes Cancer. 2017;56:303\u201313.","journal-title":"Genes Chromosomes Cancer"},{"key":"1657_CR23","doi-asserted-by":"publisher","first-page":"14109","DOI":"10.1074\/jbc.M109.078592","volume":"285","author":"PM Gordon","year":"2010","unstructured":"Gordon PM, Fisher DE. Role for the proapoptotic factor BIM in mediating imatinib-induced apoptosis in a c-KIT-dependent gastrointestinal stromal tumor cell line. J Biol Chem. 2010;285:14109\u201314.","journal-title":"J Biol Chem"},{"key":"1657_CR24","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s11010-010-0709-x","volume":"351","author":"MS Ola","year":"2011","unstructured":"Ola MS, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis. Mol Cell Biochem. 2011;351:41\u201358.","journal-title":"Mol Cell Biochem"},{"key":"1657_CR25","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1158\/0008-5472.CAN-15-3084","volume":"77","author":"C Wang","year":"2017","unstructured":"Wang C, Gu C, Jeong KJ, Zhang D, Guo W, Lu Y, et al. YAP\/TAZ-mediated upregulation of GAB2 leads to increased sensitivity to growth factor-induced activation of the PI3K pathway. Cancer Res. 2017;77:1637\u201348.","journal-title":"Cancer Res"},{"key":"1657_CR26","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/cas.13138","volume":"108","author":"H Wei","year":"2017","unstructured":"Wei H, Wang F, Wang Y, Li T, Xiu P, Zhong J, et al. Verteporfin suppresses cell survival, angiogenesis and vasculogenic mimicry of pancreatic ductal adenocarcinoma via disrupting the YAP-TEAD complex. Cancer Sci. 2017;108:478\u201387.","journal-title":"Cancer Sci"},{"key":"1657_CR27","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.celrep.2014.09.036","volume":"9","author":"M DeRan","year":"2014","unstructured":"DeRan M, Yang J, Shen CH, Peters EC, Fitamant J, Chan P, et al. Energy stress regulates hippo-YAP signaling involving AMPK-mediated regulation of angiomotin-like 1 protein. Cell Rep. 2014;9:495\u2013503.","journal-title":"Cell Rep"},{"key":"1657_CR28","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/eye.2015.251","volume":"30","author":"DK Newman","year":"2016","unstructured":"Newman DK. Photodynamic therapy: current role in the treatment of chorioretinal conditions. Eye (Lond). 2016;30:202\u201310.","journal-title":"Eye (Lond)"},{"key":"1657_CR29","unstructured":"Bressler NM, Group ToA-RMDwPTTS. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol. 2001;119:198\u2013207."},{"key":"1657_CR30","doi-asserted-by":"crossref","unstructured":"Group VIPTS. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2. Am J Ophthalmol. 2001;131:541\u201360.","DOI":"10.1016\/S0002-9394(01)00967-9"}],"container-title":["Gastric Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-025-01657-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10120-025-01657-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-025-01657-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T14:28:57Z","timestamp":1763562537000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10120-025-01657-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,8]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1657"],"URL":"https:\/\/doi.org\/10.1007\/s10120-025-01657-z","relation":{},"ISSN":["1436-3291","1436-3305"],"issn-type":[{"value":"1436-3291","type":"print"},{"value":"1436-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,8]]},"assertion":[{"value":"3 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that we have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. The Human Ethics Review Committee of Osaka University Graduate School of Medicine approved the protocol for this retrospective study and each participant provided written informed consent for study participation (ethical approval number: No. 23247). All institutional and national guidelines for the care and use of laboratory animals were followed. The Osaka University Animal Experiments Committee had given approval for the animal studies (ethical approval number: 04\u2013108-000).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}]}}